Omega Therapeutics Touts Encouraging Preclinical Data In Liver Cancer Animal Models

  • Omega Therapeutics Inc OMGA has presented new preclinical data on its lead product candidate, OTX-2002, in multiple models of hepatocellular carcinoma.
  • In non-human primates, treatment with OTX-2002 resulted in a durable reduction of MYC mRNA levels in the liver consistent with previous in vitro and in vivo studies.
  • OTX-2002 treatment decreased c-Myc mRNA, protein levels, and cell viability in multiple HCC cell lines while sparing normal cells.
  • Related: Omega Therapeutics Submits IND For Liver Cancer Candidate.
  • OTX-2002 significantly reduced tumor growth in HCC xenografts models.
  • OTX-2002 treatment is associated with decreased expression of the immune checkpoint factor PD-L1 in HCC cells, suggesting a potential role for combination therapy with immune checkpoint inhibitors.
  • Combining OTX-2002 with the existing standard of care therapies for HCC resulted in further reduction of cell viability and tumor burden in both in vitro and in vivo HCC models.
  • Price Action: OMGA shares are down 1.41% at $4.20 during the market session on the last check Thursday.

Posted In: BriefsPreclinical PhaseBiotechNewsPenny StocksHealth CareGeneral

Ad Disclosure: The rate information is obtained by Bankrate from the listed institutions. Bankrate cannot guaranty the accuracy or availability of any rates shown above. Institutions may have different rates on their own websites than those posted on Bankrate.com. The listings that appear on this page are from companies from which this website receives compensation, which may impact how, where, and in what order products appear. This table does not include all companies or all available products.

All rates are subject to change without notice and may vary depending on location. These quotes are from banks, thrifts, and credit unions, some of whom have paid for a link to their own Web site where you can find additional information. Those with a paid link are our Advertisers. Those without a paid link are listings we obtain to improve the consumer shopping experience and are not Advertisers. To receive the Bankrate.com rate from an Advertiser, please identify yourself as a Bankrate customer. Bank and thrift deposits are insured by the Federal Deposit Insurance Corp. Credit union deposits are insured by the National Credit Union Administration.

Consumer Satisfaction: Bankrate attempts to verify the accuracy and availability of its Advertisers' terms through its quality assurance process and requires Advertisers to agree to our Terms and Conditions and to adhere to our Quality Control Program. If you believe that you have received an inaccurate quote or are otherwise not satisfied with the services provided to you by the institution you choose, please click here.

Rate collection and criteria: Click here for more information on rate collection and criteria.